Skip to content
HowShorted

Arcutis Biotherapeutics, Inc. short interest in 2023

In 2023, Arcutis Biotherapeutics, Inc.'s disclosed short interest ran from 17.63% of shares outstanding on 13 Jan 2023 to 21.38% on 29 Dec 2023, a change of +3.75 percentage points. The year's high was 25.27% on 28 Apr 2023 and its low 17.63% on 13 Jan 2023, averaging 21.84% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 21.94 days on 28 Apr 2023. Full history: Arcutis Biotherapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Arcutis Biotherapeutics, Inc. in 2023

2023 in figures

Start of year
17.63% (13 Jan 2023)
End of year
21.38% (29 Dec 2023)
Change
+3.75 pp
High
25.27% (28 Apr 2023)
Low
17.63% (13 Jan 2023)
Average
21.84%
Highest days to cover
21.94 (28 Apr 2023)
SEC filings marked
9

Every report in 2023

Arcutis Biotherapeutics, Inc. short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 202317.63%12.68
31 Jan 202317.70%13.75
15 Feb 202319.50%17.19
28 Feb 202320.32%16.1210-K filed, results (8-K)
15 Mar 202322.57%9.93
31 Mar 202324.81%13.47
14 Apr 202325.19%11.98
28 Apr 202325.27%21.94
15 May 202324.44%10.1410-Q filed, results (8-K)
31 May 202321.24%8.81
15 Jun 202321.31%10.75
30 Jun 202323.99%8.00
14 Jul 202324.03%20.41
31 Jul 202324.76%19.19
15 Aug 202325.06%19.4010-Q filed, results (8-K)
31 Aug 202320.23%9.07
15 Sep 202321.54%13.06
29 Sep 202321.06%11.95
13 Oct 202322.80%7.99
31 Oct 202318.08%3.66results (8-K)
15 Nov 202318.56%7.5610-Q filed, results (8-K)
30 Nov 202322.14%6.81
15 Dec 202320.62%5.30
29 Dec 202321.38%1.81

See also: Arcutis Biotherapeutics, Inc.'s full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.